CDC panel recommends new maternal RSV vaccine to protect infants

CDC advisory committee voted to recommend Pfizer's Abrysvo vaccine for pregnant women 32-36 weeks pregnant to protect newborns from RSV.
Pfizer's vaccine is the first approved to prevent RSV disease in infants by vaccinating mothers during pregnancy.
Another new option is Sanofi's antibody shot nirsevimab that can be given to infants directly after birth for protection.
RSV is a common respiratory virus that is the leading cause of hospitalization in infants in the US.
The vaccines could help prevent thousands of RSV infections and hospitalizations in babies each year.